Overview
- Enveda completed a Phase 1 trial in 88 healthy adults and reported the drug was safe and well tolerated with an “exceptional” gastrointestinal profile and no serious adverse events.
- ENV-308 is designed to mimic lactate phenylalanine (Lac‑Phe), an exercise‑induced molecule that suppresses appetite through a pathway distinct from GLP‑1 drugs.
- The Phase 1 study found reductions in circulating leptin but was not designed to measure weight loss or improved leptin sensitivity in people, so efficacy remains unproven.
- Preclinical work in animals showed appetite suppression, weight loss with preserved lean mass, and sustained effects after dosing stopped, and Enveda plans Phase 2 trials to test weight, body composition, leptin biology, and combinations with GLP‑1 therapies.
- Even if later trials succeed, experts say longer studies and regulatory review will be needed and the pill would not replace the broad health benefits of physical exercise.